Zoetis Inc. (NYSE:ZTS) Shares Sold by DORCHESTER WEALTH MANAGEMENT Co

DORCHESTER WEALTH MANAGEMENT Co lowered its stake in Zoetis Inc. (NYSE:ZTS) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,371 shares of the company’s stock after selling 400 shares during the period. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Zoetis were worth $2,179,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC increased its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 1.9 %

Zoetis stock opened at $160.39 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a market capitalization of $71.82 billion, a price-to-earnings ratio of 29.32, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The stock’s fifty day moving average is $166.51 and its two-hundred day moving average is $177.99.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.25%. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ZTS shares. Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Finally, Morgan Stanley dropped their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus price target of $215.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.